Sterile Compounding Pharmacies Market Size & Growth Report 2028
[研究报告] 无菌复合药房市场预计将从 2021 年的 39.687 亿美元增至 2028 年的 61.9859 亿美元;预计 2021 年至 2028 年的复合年增长率为 6.6%。
个性化药物使用率的提高以及现场无菌配制带来的好处等因素推动了市场的增长。然而,产品召回和严格的监管要求阻碍了市场的增长。另一方面,在预测期内,集中或区域配制中心的开发将为市场增长创造丰厚的机会。
2021-2028 年,北美很可能继续在无菌复合药房市场占据主导地位。美国在北美市场占有最大份额,预计在预测期内将继续保持这一趋势。这主要归因于不断增长的医药支出和完善的医疗保健基础设施。例如,美国食品药品监督管理局 (FDA) 已指定 503B(根据记录,503B 被称为外包设施,有时被称为 503B 药房,并受到 FDA 的严格监控,从而建立了新的患者护理和安全水平)。此外,美国近 75% 的医院将无菌复合制剂外包给 503B 设施,以确保稳定性、应对药品短缺、获得即用型药品并延长保质期。此外,老年人口的增加和越来越多地采用定制配方而非商业产品,预计将在未来几年 推动美国无菌复合药房市场的增长。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
无菌复合药房市场:
复合年增长率(2021 - 2028 年)6.6%- 2021 年市场规模
39.7 亿美元 - 2028 年市场规模
62 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- Fagron 公司
- 三角复合药房
- B. Braun Melsungen AG
- PharMedium Healthcare Holdings, Inc.
- 弗雷森卡比公司
- Avella 专业药房
- Pencol 复合药房
- Pavilion Compounding Pharmacy,LLC。
- 佩斯药房
区域概况
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
- Injectable Drugs and Infusions
- Intravenous
- Intramuscular
- Subcutaneous
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South and Central America
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Market Insights
Benefits of On-Site Sterile Compounding Drive Market Growth
On-site compounding and sterilization can prove vital in case of an intravenous solution intended to be customized as per the patient's need. On-site manufacturing allows the active pharmaceutical ingredient (API) to be introduced to human subjects during the starting phases of early clinical drug development. Sterile extemporaneous compounding offers a flexible option to the costly, extended development of parenteral investigational products designed by the Good Manufacturing (GMP) standards. Typically, parenterally administered API for clinical studies are manufactured under GMP conditions. This potentially reduces the time required for producing a finished product needed for specific dosing.
Moreover, compounding and filtering a formulation into a sterile intravenous solution successfully is met through strong collaboration with the pharmaceutical sponsor and clinical site pharmacists, where sterility testing can be conducted efficiently.
On-site sterile compounding has gained significant attention in the global market and is one of the most impacting factors responsible for market growth. This is due to sterile compounding pharmacists are focusing more on the latest research activities, innovative techniques, quality control rules, and getting the best ingredients to meet patients' needs. For example, the National Association of Boards of Pharmacy (NABP) announced receiving funding from the Food and Drug Administration (FDA) to develop a data-sharing system to improve oversight of sterile compounding pharmacies. This new system is expected to assist in collecting, managing, and sharing information related to sterile compounding in the US. The project also aims to reduce the risk of injury, favoring patients from drug products that have been improperly compounded.
Product-Based Insights
Based on product, the sterile compounding pharmacies market is bifurcated into injectable drugs and infusions. The injectable drugs segment would account for a larger market share during 2021–2028. Injectable drugs are among the highly preferred sterile compounding products due to their faster mode of action. To avoid any adverse effects on the patients, compounded injectable drugs (defined as drugs that are diluted, mixed, reconstituted, and prepared in an office) are compounded in such an environment where appropriate safeguards are maintained against the spread of disease and components of compounded drugs that are the appropriate strength and makeup. Market players are adopting organic and inorganic growth strategies for market growth. For instance, in September 2019, QuVa Pharma, Inc. declared a considerable increase in capacity for compounded sterile injectable preparations.
Sterile Compounding Pharmacies Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 3.97 Billion |
Market Size by 2028 | US$ 6.2 Billion |
Global CAGR (2021 - 2028) | 6.6% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered | By Product
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Route of Administration-Based Insights
Based on route of administration, the sterile compounding pharmacies market is segmented into intravenous, intramuscular, and subcutaneous. The intravenous segment held the largest share of the market in 2020 and is projected to continue its dominance during the forecast period. However, the intramuscular segment is estimated to register the highest CAGR in the market during the forecast period. The intramuscular (IM) route of drug delivery is the most common route for parenteral injection. Many antibiotics, preoperative sedatives, and narcotics are given through the intramuscular route. For instance, in February 2021, Biogen, announced that the US Food and Drug Administration (FDA) approved a new intramuscular (IM) injection for "Plegridy (peginterferon beta-1a) responsible for treating multiple sclerosis (MS).
在无菌复合药房市场运营的公司采用产品创新战略来满足世界各地不断变化的客户需求,这也使他们能够在全球市场上保持自己的品牌名称。
根据产品,无菌配制药房市场分为注射剂和输液剂。
根据给药途径,无菌配制药房市场细分为静脉注射、肌肉注射和皮下注射
无菌配药药房市场规模 – 按地区划分
- 北美
- 我们
- 加拿大
- 墨西哥
- 欧洲
- 法国
- 德国
- 意大利
- 英国
- 西班牙
- 欧洲其他地区
- 亚太地区 (APAC)
- 中国
- 印度
- 韩国
- 日本
- 澳大利亚
- 亚太地区其他地区
- 中东和非洲 (MEA)
- 南非
- 沙特阿拉伯
- 阿联酋
- MEA 其他地区
- 南美洲和中美洲(SCAM)
- 巴西
- 阿根廷
- 其余的骗局
公司简介
- Fagron 公司
- 三角复合药房
- B. Braun Melsungen AG
- PharMedium Healthcare Holdings, Inc.
- 费森尤斯卡比公司
- Avella 专业药房
- Pencol 复合药房
- Pavilion 复合药房有限责任公司
- 佩斯药房
- 金沙集团
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Rising uptake of personalized medicines and the benefits of on-sterile compounding are the most significant factors responsible for the overall market growth.
Based on product type, injectable drugs took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The intravenous segment dominated the global sterile compounding pharmacies market and accounted for the largest revenue of 2,954.51 Mn in 2021.
Sterile compounding pharmacies involve creating a medication in an environment free from viruses, bacteria, or any other potentially infectious microorganisms. Such a type of compounding is intended for medications that will be administered either through an IV or an injection.
Global sterile compounding pharmacies market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for sterile compounding pharmacies market. The US is estimated to hold the largest share in the sterile compounding pharmacies market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for sterile compounding pharmacies accounting fastest growth of the region during the coming years.
Fagron, Inc., Triangle Compounding Pharmacy, B. Braun Melsungen AG, PharMedium Healthcare Holdings, Inc., Fresenious Kabi AG, Avella Specialty Pharmacy, Pencol Compounding Pharmacy, Pavilion Compounding Pharmacy, LLC., Pace Pharmacy, and SandsRx are among the leading companies operating in the global sterile compounding pharmacies market
The List of Companies - sterile compounding pharmacies market
- Fagron, Inc.
- Triangle Compounding Pharmacy
- B. Braun Melsungen AG
- PharMedium Healthcare Holdings, Inc.
- Fresenious Kabi AG
- Avella Specialty Pharmacy
- Pencol Compounding Pharmacy
- Pavilion Compounding Pharmacy, LLC.
- Pace Pharmacy
- SandsRx
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.